Serum Vascular Endothelial Growth Factor (VEGF) Levels Correlate with Tumor VEGF and p53 Overexpression in Endocrine Positive Primary Breast Cancer
- 1 January 2008
- journal article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 26 (3) , 250-255
Abstract
Vascular endothelial growth factor (VEGF) is a potent stimulator of angiogenesis, associated with unfavorable clinical characteristics in breast cancer. The aim of this study was to evaluate different angiogenic markers in endocrine-positive breast cancer patients. The authors analyzed serum and tumor samples from 71 patients with endocrine-positive operable primary breast cancer to determine the expression and the possible relationship between circulating serum VEGF levels, tumor VEGF expression, microvessel density (MVD), and other immunohistochemical parameters. Basal VEGF serum levels were significantly higher in breast cancer patients than in healthy controls. A significant correlation was observed between basal VEGF serum concentrations, microvessel density (p = 0.01) and p53 status (p = 0.004). Intratumoral VEGF expression was significantly associated with neoplastic embolization (p = 0.041) and circulating VEGF levels (p = 0.047). The results confirm that in primary endocrine-positive breast cancer serum VEGF levels are elevated and show a positive relationship with tumor VEGF and p53 overexpression.Keywords
This publication has 32 references indexed in Scilit:
- Sex-steroid regulation of vascular endothelial growth factor in breast cancerEndocrine-Related Cancer, 2006
- Systemic Effects of Surgery: Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF-β) in Patients with Breast Cancer Who Underwent Limited or Extended SurgeryBreast Cancer Research and Treatment, 2005
- Tumor-Specific Expression of Vascular Endothelial Growth Factor Receptor 2 but Not Vascular Endothelial Growth Factor or Human Epidermal Growth Factor Receptor 2 Is Associated With Impaired Response to Adjuvant Tamoxifen in Premenopausal Breast CancerJournal of Clinical Oncology, 2005
- p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implicationsThe Lancet Oncology, 2001
- The Biology of Vascular Endothelial Growth FactorEndocrine Reviews, 1997
- Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patientsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1994
- Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factorBiochemical and Biophysical Research Communications, 1992
- The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth FactorScience, 1992
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI: Journal of the National Cancer Institute, 1990